SpyGlass Pharma, Inc. (SGP)
NASDAQ: SGP · Real-Time Price · USD
23.41
-1.98 (-7.80%)
At close: May 8, 2026, 4:00 PM EDT
23.40
-0.01 (-0.04%)
After-hours: May 8, 2026, 4:04 PM EDT
Company Description
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions.
The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients.
It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021.
The company was incorporated in 2019 and is based in Aliso Viejo, California.
SpyGlass Pharma, Inc.
| Country | United States |
| Founded | 2019 |
| IPO Date | Feb 6, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Patrick Mooney |
Contact Details
Address: 27061 Aliso Creek Road, Suite 100 Aliso Viejo, California 92656 United States | |
| Phone | 949 284 6904 |
| Website | spyglasspharma.com |
Stock Details
| Ticker Symbol | SGP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 1778922 |
| CUSIP Number | 85220G109 |
| ISIN Number | US85220G1094 |
| Employer ID | 83-3044245 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Patrick H. Mooney | Chief Executive Officer and Director |
| Dr. Malik Y. Kahook M.D. | Co-Founder, President, Chief Medical Officer and Executive Chairman |
| Dr. Chetan Pujara Ph.D. | Chief Research and Development Officer |
| Glenn Sussman | Co-founder and Chief Technology Advisor |
| Dr. Jean-Frederic Viret Ph.D. | Chief Financial Officer |
| James Robert Dennewill Jr. | Chief Operating Officer |
| Rachel Gilette | Vice President of Human Resources |
| Paul Yoo O.D. | Senior Vice President of Clinical Development |
| Nina Nguyen | Senior Vice President, Regulatory and Quality |
| Long Doan | Vice President and Head of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 26, 2026 | 10-K | Annual Report |
| Mar 26, 2026 | 8-K | Current Report |
| Mar 9, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G | Filing |
| Feb 17, 2026 | SCHEDULE 13D | Filing |
| Feb 13, 2026 | SCHEDULE 13D | Filing |
| Feb 13, 2026 | SCHEDULE 13D | Filing |
| Feb 13, 2026 | 8-K | Current Report |
| Feb 13, 2026 | SCHEDULE 13G | Filing |
| Feb 10, 2026 | SCHEDULE 13D | Filing |